Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kath Kerry

- PMLiVE

Iovance up on good ASCO abstract data for cervical cancer therapy

Shares leap almost 20% after abstracts released

- PMLiVE

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Joins Imbruvica combo in front line use

- PMLiVE

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

Setback for AML candidate quizartinib

- PMLiVE

Evolving behaviour change

By Paul Tanner

- PMLiVE

It’s not the end of the world, is it?

Industry change isn’t always gradual – it can be apocalyptic

- PMLiVE

Merck claims key FDA okay for Bavencio in kidney cancer

Will help boost underwhelming revenues

- PMLiVE

Myovant’s fibroids drug clears phase 3 trial, but shares sink

Investors concerned on how it stacks up against AbbVie rival

- PMLiVE

Data regulations impeding AI use in drug research

Lack of data specialists another concern

- PMLiVE

Spinraza managed access deal in England breaks deadlock for Biogen

Patient groups remain wary, call for changes to NICE

- PMLiVE

Rare disease trials Q&A

By Gretchen Goller and Valerie Legrand

- PMLiVE

Is anybody listening?

Chris Ross explores how pharma can – indeed must – end its long history of anti-social behaviour

Lucid Group strengthens its scientific leadership and client service team with two new hires

Two Lucid Group companies, Vivid and Leading Edge, welcome new talent to their teams.Eve Raebel joins Vivid as a medical writer. Eva has 2 years’ experience as a scientific writer...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links